217 related articles for article (PubMed ID: 16246158)
21. A missense mutant myostatin causes hyperplasia without hypertrophy in the mouse muscle.
Nishi M; Yasue A; Nishimatu S; Nohno T; Yamaoka T; Itakura M; Moriyama K; Ohuchi H; Noji S
Biochem Biophys Res Commun; 2002 Apr; 293(1):247-51. PubMed ID: 12054591
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ.
Lamar KM; Bogdanovich S; Gardner BB; Gao QQ; Miller T; Earley JU; Hadhazy M; Vo AH; Wren L; Molkentin JD; McNally EM
PLoS Genet; 2016 May; 12(5):e1006019. PubMed ID: 27148972
[TBL] [Abstract][Full Text] [Related]
23. Growth factors controlling muscle development.
Bass J; Oldham J; Sharma M; Kambadur R
Domest Anim Endocrinol; 1999 Oct; 17(2-3):191-7. PubMed ID: 10527122
[TBL] [Abstract][Full Text] [Related]
24. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
Nakatani M; Takehara Y; Sugino H; Matsumoto M; Hashimoto O; Hasegawa Y; Murakami T; Uezumi A; Takeda S; Noji S; Sunada Y; Tsuchida K
FASEB J; 2008 Feb; 22(2):477-87. PubMed ID: 17893249
[TBL] [Abstract][Full Text] [Related]
25. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.
Amthor H; Hoogaars WM
Curr Gene Ther; 2012 Jun; 12(3):245-59. PubMed ID: 22554312
[TBL] [Abstract][Full Text] [Related]
26. Role of myostatin in metabolism.
Gonzalez-Cadavid NF; Bhasin S
Curr Opin Clin Nutr Metab Care; 2004 Jul; 7(4):451-7. PubMed ID: 15192449
[TBL] [Abstract][Full Text] [Related]
27. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition.
Ohsawa Y; Hagiwara H; Nakatani M; Yasue A; Moriyama K; Murakami T; Tsuchida K; Noji S; Sunada Y
J Clin Invest; 2006 Nov; 116(11):2924-34. PubMed ID: 17039257
[TBL] [Abstract][Full Text] [Related]
28. Myostatin expression and possible functions in animal muscle growth.
Kocamis H; Killefer J
Domest Anim Endocrinol; 2002 Nov; 23(4):447-54. PubMed ID: 12457953
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic potential of agents that inactivate myostatin.
Bishop A; Kambadur R; Sharma M
Expert Opin Investig Drugs; 2005 Sep; 14(9):1099-106. PubMed ID: 16144494
[TBL] [Abstract][Full Text] [Related]
30. A myostatin and activin decoy receptor enhances bone formation in mice.
Bialek P; Parkington J; Li X; Gavin D; Wallace C; Zhang J; Root A; Yan G; Warner L; Seeherman HJ; Yaworsky PJ
Bone; 2014 Mar; 60():162-71. PubMed ID: 24333131
[TBL] [Abstract][Full Text] [Related]
31. The role of myostatin and bone morphogenetic proteins in muscular disorders.
Tsuchida K
Expert Opin Biol Ther; 2006 Feb; 6(2):147-54. PubMed ID: 16436040
[TBL] [Abstract][Full Text] [Related]
32. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
[TBL] [Abstract][Full Text] [Related]
33. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle.
Zhu X; Hadhazy M; Wehling M; Tidball JG; McNally EM
FEBS Lett; 2000 May; 474(1):71-5. PubMed ID: 10828454
[TBL] [Abstract][Full Text] [Related]
34. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size.
Trendelenburg AU; Meyer A; Rohner D; Boyle J; Hatakeyama S; Glass DJ
Am J Physiol Cell Physiol; 2009 Jun; 296(6):C1258-70. PubMed ID: 19357233
[TBL] [Abstract][Full Text] [Related]
35. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
[TBL] [Abstract][Full Text] [Related]
36. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy.
Glass DJ
Curr Top Microbiol Immunol; 2010; 346():267-78. PubMed ID: 20593312
[TBL] [Abstract][Full Text] [Related]
37. Bone and morphogenetic protein signalling and muscle mass.
Sartori R; Sandri M
Curr Opin Clin Nutr Metab Care; 2015 May; 18(3):215-20. PubMed ID: 25807347
[TBL] [Abstract][Full Text] [Related]
38. Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition.
MacDonald EM; Andres-Mateos E; Mejias R; Simmers JL; Mi R; Park JS; Ying S; Hoke A; Lee SJ; Cohn RD
Dis Model Mech; 2014 Apr; 7(4):471-81. PubMed ID: 24504412
[TBL] [Abstract][Full Text] [Related]
39. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.
McPherron AC; Lawler AM; Lee SJ
Nature; 1997 May; 387(6628):83-90. PubMed ID: 9139826
[TBL] [Abstract][Full Text] [Related]
40. Femoral morphology and cross-sectional geometry of adult myostatin-deficient mice.
Hamrick MW; McPherron AC; Lovejoy CO; Hudson J
Bone; 2000 Sep; 27(3):343-9. PubMed ID: 10962344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
